Format
Sort by
Items per page

Send to

Choose Destination

Best matches for galectin-3 bladder:

Cystometric analysis of the transplanted bladder. Rocha JN et al. Int Braz J Urol. (2017)

Expression and function of phosphodiesterases (PDEs) in the rat urinary bladder. Zhu X et al. BMC Urol. (2017)

A bladder diverticulum model in rabbits. Çelebi S et al. J Pediatr Urol. (2016)

Search results

Items: 1 to 20 of 27

1.

Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3.

Fang T, Liu DD, Ning HM, Dan Liu, Sun JY, Huang XJ, Dong Y, Geng MY, Yun SF, Yan J, Huang RM.

Acta Pharmacol Sin. 2018 Dec;39(12):1885-1893. doi: 10.1038/s41401-018-0004-z. Epub 2018 May 16.

PMID:
29769742
2.

Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3.

Klover PJ, Thangapazham RL, Kato J, Wang JA, Anderson SA, Hoffmann V, Steagall WK, Li S, McCart E, Nathan N, Bernstock JD, Wilkerson MD, Dalgard CL, Moss J, Darling TN.

Elife. 2017 Jul 11;6. pii: e23202. doi: 10.7554/eLife.23202.

3.

A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.

Sutoh Yoneyama M, Tobisawa Y, Hatakeyama S, Sato M, Tone K, Tatara Y, Kakizaki I, Funyu T, Fukuda M, Hoshi S, Ohyama C, Tsuboi S.

J Biochem. 2017 Jun 1;161(6):479-492. doi: 10.1093/jb/mvw096.

PMID:
28011817
4.

T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.

Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, Montironi R, Cheng L, Blanca A, Baroni G, Minervini A, Lopez-Beltran A.

Hum Pathol. 2016 Nov;57:78-84. doi: 10.1016/j.humpath.2016.06.022. Epub 2016 Jul 26.

PMID:
27473264
5.

Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma.

Zeinali M, Adelinik A, Papian S, Khorramdelazad H, Abedinzadeh M.

Hum Immunol. 2015 Oct;76(10):770-4. doi: 10.1016/j.humimm.2015.09.036. Epub 2015 Sep 30. Review.

PMID:
26429330
6.

Diagnostic and Prognostic Significance of Serum and Tissue Galectin 3 Expression in Patients with Carcinoma of the Bladder.

Gendy HE, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O, Nour HH.

Curr Urol. 2014 Oct;7(4):185-90. doi: 10.1159/000365673. Epub 2014 Aug 20.

7.

Galectin 3 for the diagnosis of bladder cancer.

El Gendy H, Madkour B, Abdelaty S, Essawy F, Khattab D, Hammam O, El Kholy A, Nour HH.

Arab J Urol. 2014 Jun;12(2):178-81. doi: 10.1016/j.aju.2013.10.004. Epub 2013 Nov 20.

8.

Urinary IL-33 and galectin-3 increase in patients with interstitial cystitis/bladder pain syndrome (review).

Kochiashvili G, Kochiashvili D.

Georgian Med News. 2014 Jul-Aug;(232-233):12-5. Review.

PMID:
25214264
9.

Expression of the innate defense receptor S5D-SRCRB in the urogenital tract.

Miró-Julià C, Escoda-Ferran C, Carrasco E, Moeller JB, Vadekaer DF, Gao X, Paragas N, Oliver J, Holmskov U, Al-Awqati Q, Lozano F.

Tissue Antigens. 2014 Apr;83(4):273-85. doi: 10.1111/tan.12330.

PMID:
24641504
10.

Galectin-3 interactions with glycosphingolipids.

Collins PM, Bum-Erdene K, Yu X, Blanchard H.

J Mol Biol. 2014 Apr 3;426(7):1439-51. doi: 10.1016/j.jmb.2013.12.004. Epub 2013 Dec 8.

PMID:
24326249
11.

Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer.

Rodríguez Faba O, Palou J.

Curr Opin Urol. 2012 Sep;22(5):415-20. doi: 10.1097/MOU.0b013e328356ac20. Review.

PMID:
22825460
12.

A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.

Raspollini MR, Minervini A, Lapini A, Lanzi F, Rotellini M, Baroni G, Carini M.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):218-27. doi: 10.1097/PAI.0b013e31825f3264.

PMID:
22820663
13.

MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T, Saitoh H, Yamaya K, Funyu T, Habuchi T, Arai Y, Fukuda M, Ohyama C, Tsuboi S.

Int J Oncol. 2012 Jun;40(6):1831-8. doi: 10.3892/ijo.2012.1411. Epub 2012 Mar 23.

14.

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans.

Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C.

EMBO J. 2011 Jun 28;30(15):3173-85. doi: 10.1038/emboj.2011.215.

15.

Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordón-Cardo C, Sánchez-Carbayo M.

Tumour Biol. 2010 Aug;31(4):277-85. doi: 10.1007/s13277-010-0033-9. Epub 2010 Apr 17.

PMID:
20401558
16.

[Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Waalkes S, Merseburger AS, Simon A, Serth J, Kuczyk MA.

Urologe A. 2010 Mar;49(3):387-91. German.

PMID:
20238481
17.

Proteomics analysis of bladder cancer exosomes.

Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A.

Mol Cell Proteomics. 2010 Jun;9(6):1324-38. doi: 10.1074/mcp.M000063-MCP201. Epub 2010 Mar 11.

18.

Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.

Kramer MW, Kuczyk MA, Hennenlotter J, Serth J, Schilling D, Stenzl A, Merseburger AS.

Oncol Rep. 2008 Dec;20(6):1403-8.

PMID:
19020721
19.

Serum level of galectin-3 in human bladder cancer.

Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO.

J Med Invest. 2008 Feb;55(1-2):127-32.

20.

Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance.

Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H, Lensch M, Specht K, André S, Brinck U, Alken P, Gabius HJ.

Histopathology. 2007 Nov;51(5):681-90.

PMID:
17927590

Supplemental Content

Loading ...
Support Center